hC Bioscience, a pioneer in the development of tRNA-based therapeutics, received an investment from CureDuchenne Ventures, the strategic investment arm of CureDuchenne, a global nonprofit committed to finding and funding a cure for Duchenne muscular dystrophy.
Cambridge, Massachusetts--(Newsfile Corp. - February 28, 2023) - hC Bioscience, a pioneer in the development of tRNA-based therapeutics, received an investment from CureDuchenne Ventures, the strategic investment arm of CureDuchenne, a global nonprofit committed to finding and funding a cure for Duchenne muscular dystrophy. This investment will come in as an extension of hC Bioscience’s series A and serves as recognition of the potential of the Company’s tRNA-based approach to finding a cure for rare diseases like DMD.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- hC Bioscience receives investment from CureDuchenne Ventures
- tRNA offers the potential to restore clinically-meaningful levels of full-length dystrophin
- This marks the start of a relationship to develop tRNA as new treatment class for DMD
Click image above to view full announcement.
hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics to target protein dysfunction. hC Bioscience’s innovative approach to precision protein editing has the potential to treat genetically defined conditions, which account for 10-15% of all human disease. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation. The Company has raised $40 million to date and its investors include ARCH Venture Partners, Takeda Ventures, 8VC, Taiho Ventures and Panacea Venture.
Twenty years ago, CureDuchenne was created with one goal: to find and fund a cure for Duchenne muscular dystrophy, the leading genetic killer of young boys. Today, CureDuchenne is recognized as a global leader in research, patient care, and innovation for improving and extending the lives of those with Duchenne. CureDuchenne’s innovative venture philanthropy model has advanced transformative treatments for Duchenne muscular dystrophy, including 17 projects that advanced to human clinical trials and multiple projects to overcome the limitations of exon-skipping and gene therapy. In addition, CureDuchenne contributed early funding to the first FDA-approved Duchenne drug, pioneered the first and only Duchenne physical and occupational therapist certification program and created an innovative biobank and data registry, accelerating research toward a cure. For more information on how to help raise awareness and funds needed for research, please visit cureduchenne.org.
Contacts:
Savannah Beaver
(617) 804-0366
savannah@reportablenews.com
Source: hC Bioscience
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/156513
